FIELD: medicine.
SUBSTANCE: define risk factors from the anamnesis of a life and clinico-laboratory indicators: the age, degree of differentiation of a tumour, level of Testosteron-Depotum and prostates-specific antigen in blood serum (PSA), carry on prediction depending on their values, thus in addition define time from the development of hormone-resistance beginning, estimate level of painful sensations and the general condition of the patient on scale ECOG, define degree of disturbance of an emiction on international IPSS scale, establish gradation and numerical value of risk factors then define life expectancy of the patient in months under the formula: Y=-9.17+0.47•X1+1.94•X2-0.698•X3+0.01•X4 2+0.07•X3 2-1.66•X5 2+1.86•X6 2-0.0003•X7 2+0.01•X8 2, where: Y - life expectancy of the patient in months; X1, 2...8 - gradation and numerical value of risk factors, and X1 - age, years; X2 - tumour differentiation: G0 - low-grade tumour =0, G1 differentiated tumour =1, G2 - moderate-grade tumour =2, G3 - a low-grade tumour =3, G4 - an undifferentiated tumour =4; X3 - Testosteron-Depotum level in ng/ml; X4 - time from the beginning of hormone-resistance development in months; X5 - level of painful sensations of the patient: absence of pain =0, mild pain =1, moderate pain d-2, strong pain =3, intolerable pain =4; X6 - general condition of the patient on ECOG scale: activity of the patient is unlimited =0, restriction by kinds of activity of demanding efforts =1, walking and capable itself to serve, but incapable to perform any work =2, is limited capable for Self-Care =3, completely incapable of any activity =4; X7 - level of the PSA in ng/ml; X8 - degree of disturbance of an emiction at patients on international scale IPSS (from 0 to 36 points).
EFFECT: provides possibility of the prediction of life expectancy of patients in months.
1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING LIFE EXPECTANCY AT SICK OF METASTATIC CANCER OF PROSTATE | 2007 |
|
RU2340286C1 |
METHOD FOR PREDICTION OF RESPONSE TIME TO ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH PROSTATE CANCER | 2019 |
|
RU2688181C1 |
METHOD FOR PREDICTING RISK OF DEVELOPING LYMPHOGENOUS COMPLICATIONS AFTER RADICAL PROSTATECTOMY WITH PELVIC LYMPHADENECTOMY | 2021 |
|
RU2752949C1 |
METHOD FOR INTERMITTENT THERAPY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA | 2013 |
|
RU2531944C1 |
METHOD OF PREDICTING A RISK OF COMPLICATIONS OF UNIPOLAR TRANSURETHRAL ENUCLEATION OF BENIGN PROSTATIC HYPERPLASIA | 2018 |
|
RU2698623C1 |
METHOD OF TREATING BENIGN HYPERPLASIA OF PROSTATE GLAND | 2012 |
|
RU2489093C1 |
METHOD OF RESORT THERAPY OF BENIGN PROSTATIC HYPERPLASIA COMPLICATED BY CHRONIC PROSTATITIS WITH DOMINANT SYMPTOM OF NOCTURIA | 2013 |
|
RU2532353C1 |
METHOD FOR TREATING LOCAL HORMONE-RESISTANT FORMS OF PROSTATIC CANCER | 2002 |
|
RU2229880C2 |
METHOD OF PREDICTING URINARY INCONTINENCE AFTER RADICAL ROBOT-ASSISTED PROSTATECTOMY | 2023 |
|
RU2804289C1 |
METHOD OF PREDICTING LIFE DURATION OF PATIENTS WITH EXTENSIVE KIDNEY CANCER COMPLICATED BY VENOUS INVASION | 2008 |
|
RU2373864C1 |
Authors
Dates
2008-12-20—Published
2007-06-25—Filed